| Literature DB >> 35629311 |
Silvia De Francia1, Alessandro Ferretti2, Francesco Chiara1, Sarah Allegra1, Daniele Mancardi1, Tiziano Giacomo Allice3, Maria Grazia Milia3, Gabriella Gregori3, Elisa Burdino3, Claudio Avanzini3, Valeria Ghisetti3, Alessandra Durio4.
Abstract
Several important sex and gender differences in the clinical manifestation of diseases have been known for a long time but are still underestimated. The infectious Coronavirus 2019 disease pandemic has provided evidence of the importance of a sex and gender-based approach; it mainly affected men with worse symptomatology due to a different immune system, which is stronger in women, and to the Angiotensin-converting enzyme 2 and Transmembrane protease serine 2 roles which are differently expressed among the sexes. Additionally, women are more inclined to maintain social distance and smoke less. Analysis of data on the infectious Coronavirus 2019 disease testing from people admitted to the Amedeo di Savoia Hospital, a regional referral center for infectious diseases, has been applied to the whole of 2020 data (254,640 records). A high percentage of data in the dataset was not suitable due to a lack of information or entering errors. Among the suitable samples, records have been analyzed for positive/negative outcomes, matching records for unique subjects (N = 123,542), to evaluate individual recurrence of testing. Data are presented in age and sex-disaggregated ways. Analyses of the suitable sample also concerned the relation between testing and hospital admission motivation and symptoms. Our analysis indicated that a sex and gender-based approach is mandatory for patients and the National Health System's sustainability.Entities:
Keywords: Coronavirus infectious disease 2019; differences; gender; sex; tailored approach
Year: 2022 PMID: 35629311 PMCID: PMC9148110 DOI: 10.3390/life12050643
Source DB: PubMed Journal: Life (Basel) ISSN: 2075-1729
Figure 1(a) The clusters of terms defining different subjects’ categories that have undergone the COVID-19 test. (b) The clusters of terms defining different symptom categories of subjects that have undergone the COVID-19 test.
Figure 2The monthly time series of COVID-19 tests.
Age distribution parameter by period and sex for unique subjects.
| Age | ||||||||
|---|---|---|---|---|---|---|---|---|
| Period | N° | Min. | 1st Qu. | Median | Mean | 3rd Qu. | Max. | |
| I-FMAM | 39,517 | 0 | 43 | 55 | 56.86 | 74 | 108 | |
| II-JJA | 23,490 | 0 | 30 | 49 | 49.53 | 69 | 106 | |
| III-SO | 32,840 | 0 | 22 | 40 | 41.07 | 58 | 104 | |
| IV-ND | 27,695 | 0 | 32 | 50 | 49.81 | 66 | 109 | |
| I-FMAM | 15,510 | 0 | 42 | 56 | 56.25 | 73 | 108 | |
| II-JJA | 11,387 | 0 | 30 | 49 | 48.99 | 68 | 106 | |
| III-SO | 16,110 | 0 | 20 | 39 | 40.05 | 58 | 102 | |
| IV-ND | 12,967 | 0 | 31 | 49 | 48.74 | 65 | 101 | |
| I-FMAM | 24,007 | 0 | 43 | 55 | 57.26 | 75 | 107 | |
| II-JJA | 12,103 | 0 | 31 | 48 | 50.03 | 71 | 103 | |
| III-SO | 16,730 | 0 | 24 | 41 | 42.06 | 58 | 104 | |
| IV-ND | 14,728 | 0 | 33 | 50 | 50.75 | 67 | 109 | |
Figure 3Age distributions by sex (left column = Female, right column = Male), outcome test type (green = Negative, red = Positive), and periods (two pairs of four rows).
Figure 4The most common words in the corpus of epidemiological criteria.
Test outcome by subjects’ category in each year.
| Category | Period | Category | % Negative | % Positive | Total Records |
|---|---|---|---|---|---|
|
| I-FMAM | Yes | 91.3 | 8.73 | 22,216 |
| No | 76.4 | 23.64 | 48,170 | ||
| II-JJA | Yes | 98.8 | 1.20 | 4568 | |
| No | 96.4 | 3.63 | 34,019 | ||
| III-SO | Yes | 96.9 | 3.04 | 13,744 | |
| No | 89.0 | 10.96 | 44,735 | ||
| IV-ND | Yes | 86.7 | 13.32 | 2492 | |
| No | 67.8 | 32.19 | 27,026 | ||
|
| I-FMAM | Yes | 73.3 | 26.70 | 11,239 |
| No | 77.3 | 22.71 | 36,931 | ||
| II-JJA | Yes | 94.9 | 5.09 | 6188 | |
| No | 96.7 | 3.31 | 27,831 | ||
| III-SO | Yes | 94.9 | 5.11 | 6067 | |
| No | 88.1 | 11.88 | 38,668 | ||
| IV-ND | Yes | 74.4 | 25.64 | 3221 | |
| No | 66.9 | 33.08 | 23,805 | ||
|
| I-FMAM | Yes | 73.4 | 26.60 | 12,207 |
| No | 77.4 | 22.64 | 35,963 | ||
| II-JJA | Yes | 94.8 | 5.19 | 2525 | |
| No | 96.5 | 3.51 | 31,494 | ||
| III-SO | Yes | 85.3 | 14.74 | 7549 | |
| No | 89.8 | 10.19 | 37,186 | ||
| IV-ND | Yes | 69.2 | 30.83 | 11,322 | |
| No | 66.8 | 33.18 | 15,704 |
Figure 5Test outcomes for COVID-19 related symptoms in a sex-disaggregated way.
Test outcome by sex and age for asymptomatic and symptomatic COVID-19 related subjects.
| Sex | Age | Negative | Positive | |
|---|---|---|---|---|
|
| Male | From 0 to 55 | 5209 (49.8%) | 1442 (40.9%) |
| Greater than 55 | 5242 (50.2%) | 2085 (59.1%) | ||
| Female | From 0 to 55 | 6068 (51.8%) | 1371 (55.7%) | |
| Greater than 55 | 5642 (48.2%) | 1724 (55.7%) | ||
|
| Male | From 0 to 55 | 34,791 (60.6%) | 5406 (56.2%) |
| Greater than 55 | 22,609 (39.4%) | 4214 (43.8%) | ||
| Female | From 0 to 55 | 53,249 (60.2%) | 6453 (70.7%) | |
| Greater than 55 | 35,189 (39.8%) | 6276 (49.3%) |